Tarlatamab approvals and reimbursement expand small cell lung cancer options in China
Start here
Tarlatamab has been approved in China for small cell lung cancer, receiving third-line approval in April 2026 and second-line approval in May 2026. In the DeLLphi-304 trial, second-line patients treated with tarlatamab had a median overall survival of 13.6 months versus 8.3 months with chemotherapy, a 40% reduction in the risk of death (HR=0.60). Professor Yin Xiaojian has discussed the drug's clinical use, including safety management and payment access, with Fujian's Huiminbao 2026 listing it among high-cost drugs for reimbursement. Exploration of tarlatamab in earlier treatment lines is ongoing.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comProfessor Yin Xiaojian discusses tarlatamab in small cell lung cancer: clinical use, access and future development
Professor Yin Xiaojian discusses tarlatamab's clinical use after its approval in China, covering second-line efficacy in SCLC, safety management, payment access and earlier-line exploration. DeLLphi-304 showed tarlatamab extended median OS in second-line patients from 8.3 months with chemotherapy to 13.6 months, reducing death risk by 40% (HR=0.60). The drug received third-line and second-line approvals in April and May 2026, and Fujian's Huiminbao 2026 included it in its high-cost drug reimbursement list.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 23 20:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.